MKI67 and breast cancer: Moreover, at immunohistochemical level too, ER-/PR+ BC compared to ER+/PR+ cases are more likely associated to biomarkers predicting worse prognosis such as p53 and basal cytokeratin expression, high Ki67 and MKI67 mRNA levels, as well as low E-cadherin and absence of androgen receptor (27).